The best way to innovate

R&D Pipeline News

A premier information source of biopharmaceutical R&D

March 3, 2011

Get a subscription at
www.pipelinereview.com

Special Edition 1/2011

March 3, 2011

TOP 30 Biologics 2010

Features:

- Total Biologics Sales in 2010
- TOP 16 Biologics Classes 2010
- TOP 30 Blockbuster Biologics 2010
- Blockbuster Biologics 2010 by Class

Ads

PipelineReview.com

A Business Intelligence Center

Subscribe to our Free R&D Daily Newsletter and receive breaking news from biopharmaceutical R&D

Free Newsletter

Subscribe now!

LaMerie
Business intelligence

No.	Previous Year	Class of Products	2010 sales (US$ bln.)	2009 sales (US$ bln.)	Selected Branded Products
1	1	Cancer Antibodies	21.98	18.18	Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix, Arzerra, Zevalin, XGEVa...
2	2	Anti-TNF Antibodies	20.95	18.10	Enbrel, Remicade, Humira, Cimzia, Simponi
3	3	Insulin and Insulin Analogs	15.50	13.34	Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin, Apidra ...
4	4	Erythropoietins	9.25	9.56	Aranesp, Procrit Eprex, Epogen, Neo-Recormon, Epogin, ESPO, MESP, Mircera
5	6	Rec. Coagulation Factors	6.51	5.73	Novoseven, Kogenate, Helixate, Refacto, Xyntha, Advate, Recombinate, Benefix ...
6	5	Interferon beta	6.48	6.06	Avonex, Rebif, Betaferon / Betaseron
7	7	G-CSF	5.38	5.16	Neulasta, Neupogen, Neutrogin, GRAN, Neu-up
8	8	Anti-Inflammatory Antibodies	4.08	3.12	Tysabri, Xolair, Orencia, Soliris, RoActemra, Arcalyst, Stelara, Ilaris, Amevive
9	12	Ophthalmic Antibody	3.11	2.34	Lucentis
10	9	Human Growth Hormone	3.01	2.89	Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim, Omnitrope
11	10	Interferon alpha	2.72	2.61	Pegasys, Peg-Intron, Intron A
12	11	Enzyme Replacement	2.58	2.42	Cerezyme, Fabrazyme, Aldurazyme, VRIV, Myozyme, Replagal, Naglazyme, Elaprase ...
13	13	Follicle Stimulating Hormone	1.20	1.21	Gonal-f, Puregon/Follistim
14	14	Antiviral Antibody	1.04	1.08	Synagis
(15)		Other Antibodies	0.47	-	ReoPro, Prolia, Nplate
(16)		Other Proteins	3.53	-	Botox, Pulmozyme, InductOs, TNKase, Dysport, Thyrogen, Xigris, Kineret, Increlex
		Total:	107.69	91.78	

Currencies as of March 2, 2011: 1 € = 1.37726 US$; 1 CHF = 1.07917 US$; 1 Yen = 0.0121955 US$; 1 DKK = 0.184739 US$; 1 SEK = 0.157766 US$

TOP 30 Biologics in 2010 (by generic name)

# (09)	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2010 sales (vs 2009)
1 (1)	**etanercept:** Enbrel	TNF antagonist	Dimeric fusion protein of soluble TNF-R + Fc of Ig	Amgen & Wyeth & Takeda Pharmaceutical Co.	Antibody	Rheumatoid arthritis and all other approved indications	Total: **US$ 7,287 mln** (6,580)
2 (3)	**bevacizu-mab:** Avastin	VEGF	Rec humanized mab	Genentech & Roche & Chugai	Antibody	Metastatic colorectal cancer with 5-FU; 1st line NSCLC plus carboplatin & paclitaxel	Total: **US$ 6,973 mln** (5,777)
3 (4)	**rituximab**: Rituxan / MabThera	CD20	Rec chimeric full mab	Genentech; Biogen-IDEC, Roche	Antibody	Non-Hodgkin's lymphoma (NHL) etc	Total: **US$ 6,859 mln** (5,653)
4 (5)	**adalimu-mab**: Humira Pen	TNF alpha antagonist	Rec fully human mab	Abbott & Eisai	Antibody	Rheumatoid arthritis et al.	Total: **US$ 6,548 mln** (5,488)
5 (2)	**infliximab**: Remicade	TNF alpha antagonist	Rec chimeric IgG1 mab	Centocor (J&J) & Schering-Plough & Mitsubishi Tan-abe Pharma	Antibody	Rheumatoid arthritis et al.	Total: **US$ 6,520 mln** (5,934)
6 (7)	**trastuzu-mab**: Herceptin	HER2	Rec humanized mab	Genentech; Chugai, Roche	Antibody	Her2 positive met. breast cancer et al.	Total: **US$ 5,859 mln** (4,890)
7 (8)	**insulin glargine:** Lantus	Insulin receptor	Rhu basal insulin analog	Sanofi-Aventis	Protein	Type 1 and Type 2 diabetes	Total: **US$ 4,834 mln** (4,185)
8 (6)	**epoetin alfa:** Epogen / ESPO / Procrit / Eprex	Erythropoietin receptor (EPO-R)	Rhu protein	Amgen & Ortho Biotech / Janssen-Cilag (J&J) & Kyowa Hakko Kirin Pharma	Protein	Renal anemia and all other approved indications	US$ 2,524 mln + US$ 132 mln + US$ 1,934 mln Total: **US$ 4,590 mln** (5,033)

TOP 30 Biologics in 2010 (by generic name)

#	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2010 sales (vs 2009)
9 (9)	**pegfilgra-stim**: Neulasta	G-CSF receptor	Pegylated rec methio-nyl human G-CSF	Amgen	Protein	Neutropenia	Total: **US$ 3,558 mln** (3,355)
10 (11)	**ranibizu-mab:** Lucentis	VEGF	Rec human-ized Fab for intravitreal injection	Genentech & Novartis	Antibody	Wet age-related macular degeneration (AMD)	Total: **US$ 3,106 mln** (2,344)
11 (10)	**darbepo-etin alfa**: Aranesp / NESP	Erythropoietin receptor (EPO-R)	Engineered variant of rhu protein AutoInjector	Amgen & Kyowa Hakko Kirin Pharma	Protein	Anemia	US$ 2,486 mln **+** US$ 509 mln **Total: US$ 2,995 mln** (2,871)
12 (12)	**interferon beta-1a**: Avonex	Interferon beta receptor	Rhu protein for IM inj.	Biogen Idec	Protein	Relapsing forms of multiple sclerosis	Total: **US$ 2,518 mln** (2,323)
13 (13)	**interferon beta-1a:** Rebif	Interferon beta receptor	Rhu protein (prefilled syringe)	Merck Serono	Protein	Relapsing forms of multiple sclerosis	Total: **US$ 2,297 mln** (2,087)
14 (17)	**insulin aspart**: NovoLog NovoRapid	Insulin receptor	Rhu insulin analog (rapid-acting)	Novo Nordisk	Protein	Glycemic control in children and adults with diabetes mellitus	Total: **US$ 2,198 mln** (1,780)
15 (14)	**rhu insulin:** Actrapid (EU)/ Novolin (US)	Insulin receptor	Rhu insulin (short-acting) for injection, (S. cerevisiae)	Novo Nordisk	Protein	Type 1 and 2 diabetes	Total: **US$ 2,185 mln** (2,066)
16 (15)	**octocog alfa**: Advate / Recombinate	Coagulation factor VIII replacement	Rec full length factor VIII plasma / albumin free	Baxter Healthcare	Protein	Hemophilia A	**US$ 2,095 mln** (2,058) Advate and Recombinate (in process of conversion)

TOP 30 Biologics in 2010 (by generic name)

#	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2010 sales (vs 2009)
17 (16)	**insulin lispro**: Humalog Mix 50:50 premix	Insulin receptor	Rhu insulin analog	Eli Lilly	Protein	Type 1 and 2 diabetes	Total: **US$ 2,054 mln** (1,959)
18 (19)	**cetuximab**: Erbitux	EGF-R	Rec chimeric mab	Eli Lilly & BMS & Merck Serono	Antibody	Metastatic colo-rectal carcinoma and other labels	Total: **US$ 1,791 mln** (1,629)
19 (20)	**peginter-feron alfa-2a**: Pegasys	Interferon alpha receptor	Pegylated rhu protein	Roche	Protein	Chronic hepatitis C virus infection + Copegus	Total: **US$ 1,775 bln** (1,538)
20 (18)	**interferon beta-1b**: Betaseron / Betaferon	Interferon beta receptor	Rhu protein	Berlex & Bayer Schering Pharma	Protein	All relapsing forms of multiple sclerosis	Total: **US$ 1,661 mln** (1,649)
21 (23)	**eptacog alfa:** NovoSeven	Induction of coagulation in the presence of alloantibo-dies to F. VIII	Rhu protein	Novo Nordisk	Protein	Hemophiliacs with alloantibodies	Total: **US$ 1,483 mln** (1,292)
22 (25)	**insulin aspart**; NovoMix 50;	Insulin receptor	Rhu insulin analog	Novo Nordisk	Protein	Type 1 and 2 diabetes	Total: **US$ 1,445 mln** (1,187)
23 (-)	**onabotuli-numtoxinA**: Botox	Neuromus-cular transmission (SNAP-25 cleavage)	Neurotoxin protein from Clostridium botulinum type A	Allergan Phar-maceuticals & GlaxoSmith-Kline Japan & China)	Protein	Medical and esthetic indications	Total: **US$ 1,414 mln**

TOP 30 Biologics in 2010 (by generic name)

#	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2010 sales (vs 2009)
24 (21)	**epoetin beta**: NeoRecor-mo / Epogin / Epoch	Erythropoietin receptor (EPO-R)	Rhu protein	Roche	Protein	Renal anemia and all other approved indications	**Total: US$ 1,387 mln** (1,450)
25 (24)	**Rec Anti-hemophilic Factor:** Kogenate FS	F. VIII substitution	Rhu protein formulated with sucrose (BHK)	Bayer Schering Pharma	Protein	Hemophilia A	Total: **US$ 1,383 mln** (1,207)
26 (22)	**filgrastim**: Neupogen;	G-CSF receptor	Rhu protein	Amgen	Protein	Neutropenia	Total: **US$ 1,286 bln** (1,341)
27 (-)	**insulin detemir**: Levemir	Insulin receptor	Rhu basal insulin analogue	Novo Nordisk	Protein	Insulin-dependent diabetes	Total: **US$ 1,271 mln** (954)
28 (27)	**natalizu-mab:** Tysabri	Alpha4/beta1/ 7 integrin	Rec humanized IgG4 mab	Biogen Idec & Elan	Antibody	RR multiple sclerosis	Total: **US$ 1,230 mln** (1,060)
29 (28)	**human insulin:** Humulin 50:50	Insulin receptor	Rhu insulin (mix isophane suspension)	Eli Lilly	Protein	Type 1 and 2 diabetes	Total: **US$ 1,089 mln** (1,022)
30 (26)	**palivizu-mab**: Synagis	Epitope on RS virus	Rec humanized full mab	MedImmune	Antibody	Propylaxis of RSV infection	Total: **US$ 1,038 mln** (1,082)

Group 1: Cancer Antibodies - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1891	Avastin; bevacizumab	Vascular endothelial growth factor (VEGF)	Rec humanized mab	Roche	Antibody	1st and 2nd line metastatic colorectal cancer with 5-FU-based chemotherapy	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 sales of CHF 6,461 mln (+9% vs previous year) = **US$ 6,973 mln**
1825	Rituxan / MabThera; rituximab;	CD20	Rec chimeric full mab	Roche (Genentech) & Biogen-IDEC	Antibody	Non-Hodgkin's B-Cell Lymphoma	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 sales of CHF 6,356 mln (+9% vs previous year) = **US$ 6,859 mln**
1869	Herceptin; trastuzumab	HER2	Rec humanized mab	Roche (Genentech & Chugai)	Antibody	Her2 positive metastatic breast cancer and all other approved indications	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 sales of CHF 5,429 mln (+7% vs previous year) = **US$ 5,859 mln**
1847	Erbitux; cetuximab; IMC-C225; EMD-271786	EGF-R	Rec chimeric mab	Eli Lilly (from ImClone acquisition) & Bristol-Myers Squibb (BMS) & Merck Serono	Antibody	Irinotecan refractory metastatic colorectal carcinoma and all other approved indications	Mar-ket	BMS PR Jan 27, 2011 - BMS reported 2010 sales of US$ 662 mln (-3% vs previous year) and Merck Serono 2010 sales of € 820 mln = US$ 1,129 mln (+18% vs previous year) source = **US$ 1,791 mln**
1790	Vectibix; panitumu-mab	EGF-R	Rec fully human IgG2 full mab	Takeda Pharmaceutical Co. & Amgen	Antibody	3rd line metastatic colorectal cancer et al	Mar-ket	Amgen PR Jan 24, 2011 - 2010 sales were US$ 288 mln (+24% vs prevous year); Takeda's Q1-Q3 sales in Japan in Fiscal Year 2010 were Yen 5.9 bln, extrapolated to full year = Yen 7.9 bln =US$ 96 mln source = **US$ 384 mln**

Group 1: Cancer Antibodies - II

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1820	Arzerra, ofatumumab HuMax-CD20	CD20	Rec fully human IgG1 mab	GlaxoSmith-Kline (GSK) & Genmab	Antibody	Relapsed or refr-actory chronic lymphocytic leukemia (CLL)	Mar-ket	GSK PR Feb 3, 2011 - Newly launched, with 2010 sales of GBP 31 mln = **US$ 50.4 mln***
2072	Zevalin; ibritumomab tiuxetan	CD20	Yttrium-90 labelled murine IgG1 mab	Bayer Schering Pharma & Spectrum Phar-maceuticals	Antibody	Relapsed or refractory, low-grade or follicular B-cell NHL	Mar-ket	Spectrum Pharmaceuticals PR Nov 4, 2010 - 9-month sales by Spectrum in the US in 2010 were US$ 21.1 mln, extrapolated to Full Year 2010 would be **US$ 28.1 mln** (vs US$ 15.7 mln in 2009)
2117	Mylotarg; gemtuzumab ozogamicin	CD33 and DNA double stand breaking	Rhu IgG4 mab conjugated with calicheamicin	Pfizer (acquired Wyeth)	Antibody	CD33+ relapsed AML	Disco ntinue d	PDL Homepage Feb 28, 2011 - 2010 sales until discontinuation of marketing were **US$ 24.9 mln**
11234	XGEVA; Denosumab; AMG-162	Receptor Activator for Nuclear Factor kappa B Ligand (RANKL)	Rec fully human IgG2 mab for SC injection	Amgen & Daiichi	Antibody	Prevention of skeletal-related events/SRE; bone metastasis)	Mar-ket	Amgen Presentation Jan 11, 2011 - First sales in the US after approval in Nov 2010 were **US$ 8 mln**
1963	Removab; catumaxo-mab; anti-EpCAM x anti-CD3	EpCAM (cancer target) and CD3 (T cell recruitment)	Bispecific rat/murine hybrid mab (tri-functional)	Fresenius Biotech (TRION Pharma)	Antibody	Malignant ascites	Mar-ket	Fresenius PR Feb 23, 2011 - 2010 sales of € 3 mln (so far marketed primarily in Germany, Austria and France) = **US$ 4.1 mln**
								Total = **US$ 21.982 bln** (US$ 18.182 bln in 2009)

* as of March 2, 2011: 1 GBP = 1.62542 US$

Group 2: TNF Antagonist Biologics - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
6605	Enbrel; etanercept	TNF antagonist	Dimeric fusion protein of soluble TNF-R + CH2 and CH3 domains of Fc of Ig	Amgen & Pfizer (acquired Wyeth) & Takeda Pharmaceutical Co.	Antibody	Moderate to severe rheumatoid arthritis	Mar-ket	Amgen PR Jan 24, 2011 - Amgen reported 2010 US and Canada sales of US$ 3,534 mln (+1.2% vs previous year); Pfizer's internatio-nal sales in 2010 were US$ 3,274 mln source Takeda Q1-Q3 sales of fiscal year 2010 were Yen 29.5 mln, extrapolated to full year = Yen 39.3 bln = US$ 479 mln source Total sales of **US$ 7,287 mln**
6571	Humira Pen; adalimumab;	TNF alpha antagonist	Rec fully human mab	Abbott & Eisai	Antibody	Moderate to severe rheumatoid arthritis	Mar-ket	Abbott 2010 Earnings PR Jan 26, 2011 - 2010 sales were **US$ 6,548 mln** (+19.3% vs previous year) Eisai expects full year sales in Japan in FY 2010 of Yen 14 bln source
6587	Remicade; infliximab	TNF alpha antagonist	Rec chimeric IgG1 mab	Centocor (J&J) & Merck & Co. (acquired Schering-Plough) & Mitsubishi Tanabe Pharma	Antibody	Moderately to severely active rheumatoid arthritis	Mar-ket	J&J PR Jan 25, 2011 - J&J US sales in 2010 were US$ 3,099 mln (+0.4% vs previous) and exports to partners of US$ 1,487 mln(+24.3% vs previous year); sales in Merck territories outside the US in 2010 were US$ 2,714 mln (+ 17% vs previous year) source MTP sales in Apr-Dec 2010 were Yen 46.7 bln source and in Jan-Mar 2010 were Yen 11.3 bln source totalling Yen 58 bln = US$ 707 mln in calendar year. 2010 Total sales of **US$ 6,520 mln**

Group 2: TNF Antagonist Biologics - II

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
6573	Simponi; golimumab; CNTO 148; CNTO-148	TNF alpha antagonist	Rec fully human IgG1 mab, once monthly SC	Merck & Co. (acquired Schering-Plough) & Centocor (J&J) & Mitsubishi Tanabe Pharma	Antibody	Rheumatoid arthritis (RA); psoriatic arthritis; ankylosing spondylitis	Mar-ket	Merck & Co 2010 Sales Feb 3, 2011 - 2010 sales by Merck & Co outside the US and the MTP territories in 18 countries were US$ 97 mln. J&J reported 2010 sales of US$ 226 mln source. Total sales of **US$ 323 mln**
650	CIMZIA; certolizumab pegol; CDP-870	TNF-alpha (soluble and membrane bound)	PEGylated rec human-ized Fab' fragment	UCB Pharma (ex Celltech)	Antibody	Moderate to severe Crohn's disease and RA	Mar-ket	UCB PR Mar 2, 2011 - 2010 sales were € 198 mln (+163% vs previous year) = **US$ 273 mln**
								Total: **US$ 20.951 bln** (US$ 18.097 bln in 2009)

Group 3: Insulin - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1379	Lantus; insulin glargine	Insulin receptor	Rhu basal insulin analog for once-daily SC injection	Sanofi-Aventis	Protein	Type 1 and Type 2 diabetes	Mar-ket	Sanofi-Aventis PR Feb 9, 2011 - 2010 sales of € 3,510 mln (+9.1% vs previous year) = **US$ 4,834 mln**
1223	NovoLog (US) / NovoRapid (EU); insulin aspart	Insulin receptor	Rhu insulin analog (rapid-acting) for injection, produced in S.cerevisiae	Novo Nordisk	Protein	Glycemic control in children and adults with diabetes mellitus	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of DKK 11,900 mln (+22% vs previous year) = **US$ 2,198 mln**
1380	Actrapid (EU)/ Novolin (US); rhu insulin	Insulin receptor	Rhu insulin (short-acting) for injection, produced in S.cerevisiae	Novo Nordisk	Protein	Type 1 and 2 diabetes	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of human insulins were DKK 11,827 mln (+5% vs previous year) = **US$ 2,185 mln**
1324	Humalog Mix 50:50; premix insulin lispro	Insulin receptor	Mixture of soluble rhu insulin analog (50 %) with insuline-protamine precipitate (50 %)	Eli Lilly	Protein	Type 1 and 2 diabetes	Mar-ket	Lilly Product Sales Jan 27, 2011 - 2010 sales of **US$ 2,054 mln** (+5% vs previous year)

Group 3: Insulin - II

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
6984	NovoMix 50; premix insulin aspart	Insulin receptor	Soluble (50 %) and protamine-crystallized (50 %) rhu insulin ana-log aspart	Novo Nordisk	Protein	Type 1 and 2 diabetes	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of DKK 7,821 mln (+20% vs previous year) = **US$ 1,445 mln**
1238	Levemir; insulin detemir	Insulin receptor	Rec human basal insulin analogue for once-daily injection	Novo Nordisk	Protein	Children and adults with insulin-dependent diabetes	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of DKK 6,880 mln (+32% vs previous year) = **US$ 1,271 mln**
8893	Humulin 50:50; premix human insulin	Insulin receptor	Rhu insulin produced in E.coli, mix of 50 % soluble human insulin and 50 % insulin isophane suspension	Eli Lilly	Protein	Type 1 and 2 diabetes	Mar-ket	Lilly Product Sales Jan 27, 2011 - 2010 sales of **US$ 1,089 mln** (+6% vs previous year)
6982	Apidra; insulin glulisine	Insulin receptor	Mealtime short acting rhu insulin analog	Sanofi-Aventis	Protein	Type 1 and 2 diabetes mellitus	Mar-ket	Sanofi-Aventis PR Feb 9, 2011 - 2010 sales of € 177 mln (+24.1% vs previous year) = **US$ 244 mln**
7061	Insuman Comb / Rapid / Basal / Infusat;	Insulin receptor	Rhu basal insulin produced in E.coli	Sanofi-Aventis	Protein	Type 1 and 2 siabetes	Mar-ket	Sanofi-Aventis PR Feb 9, 2011 - 2010 sales of € 133 mln (+1.5% vs previous year) = **US$ 183 mln**
								Total = **US$ 15.503 bln** (US$ 13.339 bln in 2009)

Group 4: Erythropoiesis Stimulating Agents (ESA) - I								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
52	Aranesp; darbepoetin alfa	Erythropoietin receptor (EPO-R)	Engineered variant of rec hu hormone + AutoInjector	Amgen	Protein	Chronic kidney disease (once monthly) and all other approved indications	Mar-ket	Amgen PR Jan 24, 2011 - 2010 sales were **US$ 2,486 mln** (-6% vs previous year)
165	NESP; darbepoetin; KRN-321	Erythropoietin receptor (EPO-R)	Glycoengineered rhu protein	Kyowa Hakko Kirin Pharma (from Amgen)	Protein	Renal anemia	Mar-ket	Kyowa Hakko Kirin 2010 Product Sales Jan 28, 2011 - Nesp sales in 2010 were Yen 41.7 bln (+18% vs previous year) = **US$ 509 mln**
161	Epogen; epoetin alfa	Erythropoietin receptor (EPO-R)	Rhu erythropoietin alfa	Amgen	Protein	Renal anemia and all other approved indications	Mar-ket	Amgen PR Jan 24, 2011 - Amgen's 2010 sales were **US$ 2,524 mln** (-2% vs previous year)
162	ESPO; epoetin alfa	Erythropoietin receptor (EPO-R)	Rhu protein	Kyowa Hakko Kirin Pharma (from Amgen)	Protein	Renal anemia	Mar-ket	Kyowa Hakko Kirin 2010 Product Sales Jan 28, 2011 - Espo 2010 sales were Yen 10.8 bln (-20% vs previous year) = **US$ 132 mln**
1899	Procrit / Eprex / Erypo; epoetin alfa	Erythropoietin receptor (EPO-R)	Rec human glycoprotein	Ortho Biotech / Janssen-Cilag (J&J) (from Amgen)	Protein	Chemotherapy induced anemia and all other approved indications	Mar-ket	J&J PR Jan 25, 2011 - 2010 sales of **US$ 1,934 mln** (-13.9% vs previous year)
163	Neo-Recormon; epoetin beta	Erythropoietin receptor (EPO-R)	Rhu protein	Roche	Protein	Renal anemia and all other approved indications	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 combined sales of NeoRecormon and Epogin were CHF 1,285 mln (-15% vs previous year) = **US$ 1,387 mln**, of which Epogin sales were Yen 40 bln (US$ 488 mln)

Group 4: Erythropoiesis Stimulating Agents - II								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
164	Epogin; Epoch; epoetin beta	Erythropoietin receptor (EPO-R)	Rhu protein	Roche (Chugai)	Protein	Renal anemia. Chemotherapy induced anemia	Mar-ket	Chugai Suppl Materials Feb 2, 2011 - Epogin sales in 2010 were Yen 40 bln (-9.9% vs previous year)
207	Mircera; Methoxy polyethylene glycol-epoetin beta; CERA	Erythropoietin receptor (EPO-R)	Continuous erythro-poiesis receptor activator (pegylated)	Roche	Protein	Renal anemia due chronic kidney disease +/- dialysis	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 sales of CHF 255 mln (+51% vs previous year)= **US$ 275 mln**; now available in over 100 countries
								Total: **US$ 9.247 bln** (US$ 9.562 bln in 2009)

Group 5: Coagulation Factors - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
106	Advate; octocog alfa; antihemo-philic factor plasma/ albumin-free	Coagulation factor VIII replacement	Rec full length coagulation factor VIII plasma/ albumin free	Baxter Healthcare	Protein	Hemophilia A	Mar-ket	Baxter 2010 Sales - 2010 combined sales of Advate and Recombinate were **US$ 2,095 mln** (+2% vs previous year)
117	NovoSeven; eptacog alfa; rFVII	Substitution of coagulation F. VIIa	Rhu activated factor VII in BHK	Novo Nordisk (from Zymogenetics)	Protein	Hemorrhage in hemophiliacs with alloantibodies	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of DKK 8,030 mln (+14% vs previous year) = **US$ 1,483 mln**
119	Kogenate FS (BAY 14-2222) + BIO-SET	F. VIII substitution	Rhu protein formulated with sucrose (BHK)	Bayer Schering Pharma	Protein	Hemophilia A	Mar-ket	Bayer 2010 Full Year Investor Briefing Feb 28, 2011 - 2010 sales were € 1,004 mln (+13.1% vs previous year) = **US$ 1,383 mln**
150	BeneFix; nonacog alfa	F. IX substitution	Rec hu protein	Pfizer (acquired Wyeth) & Biovitrum	Protein	Hemophilia B	Mar-ket	Pfizer 2010 Earnings PR Feb 1, 2011 - 2010 sales were **US$ 643 mln**
10106	Helixate FS / Helixate NexGen	F. VIII substitution	Rhu protein formulated with sucrose	CSL Behring (manufactured by Bayer Schering Pharma)	Protein	Hemophilia A	Mar-ket	CSL Presentation Feb 16, 2011 - Sales in H1 of Fiscal Year 2010/11 were US$ 238 mln and sales in H2 of Fiscal Year 2009/10 were US$ 242 mln source corresponding to 2010 Calendar Year sales of **US$ 480 mln** (+2.8% vs previous calendar year)
114	Xyntha (USA) / Refacto (EU); moroctocog alfa (AF-CC)	Substitution of coagulation factor VIII	Albumin free (AF) rhu B-domain deleted factor VIII	Pfizer (acquired Wyeth) & Biovitrum	Protein	Hemophilia A	Mar-ket	Pfizer 2010 Earnings PR Feb 1, 2011 - Combined product sales of Refacto and Xyntha in 2010 were US$ 404 mln; co-promotion sales of Swedish Orphan Biovitrum in 2010 were SEK 89.4 mln = US$ 14.1 mln source Total sales of **US$ 418 mln**

Group 6: Coagulation Factors - II								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
6374	Recothrom; rhThrombin	Fibrinogen	Rec hu protein in spray formulation produced in CHO cells	Bristol-Myers Squibb (BMS) (acquired Zymogenetics)	Protein	Hemostasis in surgery	Mar-ket	BMS PR Jan 27, 2011 - BMS reported US$ 15 mln sales related to Q4/2010 after completion of acquisition of Zymogenetics. Q1/2010 sales were US$ 9 mln source; and in Q2/2010 of US$ 11.9 mln source; Estimated full year 2010 sales of **US$ 49.4 mln**
								Total = **US$ 6.514 bln** (US$ 5.728 bln in 2009)

Group 6: Interferon beta

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1556	Avonex; interferon beta-1a	Interferon beta receptor	Rhu protein for IM injection once a week	Biogen Idec	Protein	Relapsing forms of multiple sclerosis	Mar-ket	Biogen Idec PR Feb 1, 2011 - 2010 sales of **US$ 2,518 mln** (+8% vs previous year)
1534	Rebif; interferon beta-1a	Interferon beta receptor	Rhu protein (prefilled syringe)	Merck Serono	Protein	Relapsing forms of multiple sclerosis	Mar-ket	Merck KGaA PR Feb 21, 2011 - 2010 sales of € 1,668 mln (+8.6% vs previous year) = **US$ 2,297 mln**
1501	Betaseron / Betaferon; interferon beta-1b	Interferon beta receptor	Rhu protein	Berlex / Bayer Healthcare Pharma-ceuticals	Protein	All relapsing forms of multiple sclerosis	Mar-ket	Bayer 2010 Full Year Investor Briefing Feb 28, 2011 - 2010 sales of € 1,206 mln (-0.7% vs previous year) = **US$ 1,661 mln**
								Total: **US$ 6.476 bln** (US$ 6.059 bln in 2009)

Group 7: Granulocyte Colony Stimulating Factor (G—CSF)

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1874	Neulasta; pegfilgrastim	G-CSF receptor	Pegylated rec methionyl human G-CSF	Amgen	Protein	Myelosuppressive chemotherapy with at least 17 % risk of febrile neutropenia	Mar-ket	Amgen PR Jan 24, 2011 - 2010 sales were **US$ 3,558 mln** (+6% vs previous year)
1943	Neupogen; filgrastim	G-CSF receptor	Rhu protein	Amgen	Protein	Neutropenia	Mar-ket	Amgen PR Jan 24, 2011 - Amgen's 2010 sales were **US$ 1,286 mln** (-0.2% vs previous year)
9986	Neu-up; nartograstim	G-CSF receptor	Rhu protein	Yakult Honsha (from Kyowa Hakko Kirin Pharma)	Protein	Neutropenia	Mar-ket	Kyowa Hakko Kirin 2010 Product Sales Jan 28, 2011 - Transferred product rights to Yakult Honsha effective March 1, 2010. Combined product sales of GRAN for the full year 2010 and Neu-Up until february 28, 2010 were YEN 14.4 bln (-15% vs previous year) **US$ 176 mln**
9983	Gran; filgrastim	G-CSF receptor	Rhu protein	Kyowa Hakko Kirin Pharma (from Amgen)	Protein	Neutropenia	Mar-ket	Kyowa Hakko Kirin 2010 Product Sales Jan 28, 2011 - Combined product sales of GRAN for the full year 2010 and Neu-Up until february 28, 2010 were YEN 14.4 bln (-15% vs previous year)
2345	Neutrogin; lenograstim	G-CSF receptor	Rhu protein	Chugai & Roche	Protein	Chemotherapy-induced neutropenia	Mar-ket	Roche Financial Report 2010 - 2010 sales of CHF 331 mln (-16% vs previous year) = **US$ 357 mln**
								Total = **US$ 5.377 bln** (US$ 5.162 bln in 2009)

Group 8: Anti-Inflammatory Antibodies - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
1476	Tysabri; Antegren; natalizumab; AN100226	Alpha4/beta1/ 7 integrin	Rec humanized IgG4 mab	Biogen Idec & Elan	Antibody	RR multiple sclerosis	Mar-ket	Biogen Idec PR Feb 1, 2011 - Global in-market sales in 2010 were **US$ 1,230 mln** (+16% vs previous year)
6537	Orencia; abatacept; CTLA4-Ig	B7-1 (CD80) and B7-2 (CD86)	Rec fusion protein of CTLA4+ Fc of IgG1 (hinge, CH2 + CH3)	Bristol-Myers Squibb	Antibody	Adult rheumatoid arthritis and juvenile idiopathic arthritis	Mar-ket	BMS PR Jan 27, 2011 - 2010 sales of **US$ 733 mln** (+22% vs previous year)
90	Xolair; omalizumab;	IgE	Rec humanized mab	Roche (Genentech) & Novartis	Antibody	Severe allergic asthma in adults and adolescents (age 12 or above)	Mar-ket	Roche Financial Report 2010 - Roche 2010 sales were CHF 641 mln (+8% vs previous year); Novartis sales were US$ 369 mln (+9% vs previous year) source **US$ 692 mln**
37	Soliris; eculizumab; H5G1.1	Complement C5 antagonist	Rec human-ized (hybrid IgG2/4) full mab	Alexion Phar-maceuticals	Antibody	Paroxysmal nocturnal hemoglobinuria (PNH)	Mar-ket	Alexion PR Feb 10, 2011 - 2010 sales were **US$ 541 mln** (+40% vs previous year)
6545	RoActemra (EU); Actemra; tocilizumab	Interleukin-6 receptor (IL-6R) antagonist	Rec humanized mab	Roche (Chugai)	Antibody	Moderate to severe rheuma-toid arthritis (RA)	Mar-ket	Roche Financial Report 2010 - 2010 sales of CHF 397 mln (+177% vs prevoius year), now available in some 50 countries = **US$ 428 mln**
540	STELARA; ustekinumab CNTO-1275	IL-12 (p40) and IL-23	Rec fully human IgG1 full mab (UltiMAb)	Johnson & Johnson (Centocor)	Antibody	Moderate to severe psoriasis	Mar-ket	Johnson & Johnson PR Jan 25, 2011 - 2010 sales of **US$ 393 mln**
9054	Ilaris; Canakinuma b; ACZ-885; ACZ885	IL-1 beta antagonist	Rec fully human IgG1 mab	Novartis (with Medarex technology)	Antibody	CAPS, incl. Muckle Wells Syndrome	Mar-ket	Novartis PR Jan 27, 2011 - 2010 sales of **US$ 26 mln** (in year after first approval)

Group 8: Anti-Inflammatory Antibodies - II								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
6546	ARCALYST; rilonacept; Il-1 trap	Interleukin-1 (IL-1) antagonist	Trap (2 IL receptor do-mains + CH2 +CH3 of Fc)	Regeneron Pharma-ceuticals	Antibody	Cryopyrin-asso-ciated periodic syndromes (CAPS)	Mar-ket	Regeneron Pharmaceuticals PR Feb 17, 2011 - In 2010 realized net sales of **US$ 20.5 mln** (+11.4% vs previous year)
572	Amevive; alefacept	CD2	Rec dimeric fusion protein of LFA3-ECD and CH2 and CH3 domains of Fc of IgG1 for injection	Astellas Pharma	Antibody	Psoriasis	Mar-ket	Astellas Pharma Q3 FY 2010 Earnings Feb 1, 2011 - Based on Q1-3, FY 2010, sales data in North America, Fiscal Year 2010 sales forecast of **US$ 12 mln** (-5.5% vs previous year)
								Total: **US$ 4.076 bln** (US$ 3.117 bln in 2009)

Group 9: Ophthalmic Antibody								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
6306	Lucentis; ranibizumab; RG3645; RG-3645	Vascular endothelial growth factor (VEGF)	Rec humanized Fab for intravitreal injection	Roche (Genentech) & Novartis	Antibody	Wet age-related macular degeneration (AMD)	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - Roche sales of Lucentis in 2010 were CHF 1,458 mln = US$ 1,573 mln (+27%); Novartis sales of Lucentis in 2010 were US$ 1,533 mln (+24%) source = **US$ 3.106 bln** (vs. US$ 2.34 bln in 2009)

Group 10: Human Growth Hormone (hGH)								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
1291	Norditropin; somatropin	hGH receptor	Rhu protein	Novo Nordisk	Protein	Growth hormone deficiency	Mar-ket	Novo Nordisk PR Feb 02, 2011 - 2010 sales of DKK 4,803 mln (+9% vs previous year) = **US$ 887 mln**
1289	Genotropin; somatropin	hGH) receptor	Rhu protein with SC inj. devices	Pfizer	Protein	Growth hormone deficiency	Mar-ket	Pfizer 2010 Earnings PR Feb 1, 2011 - 201 sales were **US$ 885 mln** (-1% vs previous year)
1288	Nutropin; Nutropin AQ; somatropin	hGH receptor	Rhu protein	Genentech (Roche)	Protein	Growth hormone deficiency	Mar-ket	Roche Financial Report 2010 - 2010 sales in Roche territories were CHF 405 mln (+5% vs previous year) = **US$ 437 mln**
1290	Humatrope; somatropin	hGH receptor	Rhu protein for SC injection	Eli Lilly	Protein	Growth hormone deficiency	Mar-ket	Lilly Product Sales Jan 27, 2011 - 2010 sales of **US$ 422 mln** (-6% vs previous year)
1292	Saizen; somatropin	hGH receptor	Rhu protein	Merck Serono	Protein	Growth hormone deficiency	Mar-ket	Merck KGaA PR Feb 21, 2011 - 2010 sales of € 226 mln (+18% vs previous year) = **US$ 311 mln**
8750	Nutropin AQ; somatropin	hGH receptor	Rhu protein	Ipsen (from Genentech)	Protein	Growth hormone defiency	Mar-ket	Ipsen PR Feb 2, 2011 - 2010 sales of € 48.4 mln (+18.2% vs previous year) = **US$ 67 mln**
								Total: **US$ 3.009 bln** (US$ 2.886 bln in 2009)

Group 11: Interferon alpha

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
861	Pegasys; peg-interferon alfa-2a	Interferon alpha receptor	Pegylated rhu protein	Roche	Protein	Chronic hepatitis C virus infection + Copegus	Mar-ket	Roche 2010 Earnings PR Feb 2, 2011 - 2010 sales of CHF 1,645 mln (+2% vs previous year) = **US$ 1,775 mln**
794	PegIntron; pegylated interferon alfa-2b	Interferon alpha receptor	Pegylated (12 kDa) rec human protein	Merck & Co. (acquired Schering-Plough)	Protein	Hepatitis C virus infection plus/minus ribavirin; retreatment after previous IFN treatment failure	Mar-ket	Merck & Co 2010 Sales Feb 3, 2011 - 2010 sales of **US$ 737 mln** (-13% vs previous year)
920	Intron A; interferon alpha-2b	Interferon alpha receptor	Rhu protein	Merck & Co. (acquired Schering-Plough)	Protein	Oncology	Mar-ket	Merck & Co 2010 Sales Feb 3, 2011 - 2010 sales of **US$ 209 mln** (-9% vs previous year)
								Total: **US$ 2.721 bln** (US$ 2.613 bln in 2009)

Group 12: Enzyme Replacement Therapies

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
7822	Cerezyme; imiglucerase	Beta-gluco-cerebrosidase enzyme replacement	Rhu protein	Genzyme	Protein	Type 1 Gaucher disease	Mar-ket	Genzyme 2010 Earnings PR Feb 16, 2011 - 2010 sales were **US$ 720 mln** (-9% vs previous year)
1192	Lumizyme (2000 L BLA) / Myozyme (160 L BLA); alglucosidase alpha	Alglucosidase alpha replacement	Rec hu enzyme	Genzyme Corp	Protein	Pompe disease	Mar-ket	Genzyme PR Jan 11, 2011 - 2010 sales of **US$ 412 mln** (+27% vs previous year)
1157	Elaprase; idursulfase; iduronate-2-sulfatase	Iduronate-2-sulfatase enzyme replacement	Rhu protein	Shire & Genzyme	Protein	Hunter syndrome (MPS-II)	Mar-ket	Shire PR Feb 10, 2011 - 2010 sales of **US$ 403.6 mln** (+14% vs previous year)
1381	Replagal; GA-agalsida-se alfa	Alpha-galactosidase ERT	Rhu protein	Shire & Dainippon Sumitomo	Protein	Fabry disease	Mar-ket	Shire PR Feb 10, 2011 - 2010 sales of **US$ 351.3 mln** (+81% vs previous year)
1161	Naglazyme; galsulfase; rhASB	Arylsulfatase B enzyme replacement	Rhu protein	Biomarin Pharmaceutical & AnGes MG	Protein	Mucopolysaccharidosis VI (MPS VI)	Mar-ket	Biomarin PR Feb 17, 2011 - 2010 sales of **US$ 192.7 mln** (+14.2% vs previous year)
1176	Fabrazyme; agalsidase beta	Alpha-galactosidase A enzyme replacement	Rhu protein	Genzyme	Protein	Fabry disease	Mar-ket	Genzyme PR Jan 11, 2011 - 2010 sales were **US$ 188 mln** (-56% vs previous year)
1159	Aldurazyme; laronidase	Alpha-L-iduronidase ERT	Rhu protein	Biomarin Pharmaceuticals & Genzyme	Protein	Mucopolysaccharidosis I (MPS I)	Mar-ket	Genzyme 2010 Earnings PR Feb 16, 2011 - 2010 sales of **US$ 166.8 mln** (+7.6% vs previous year)
1385	VPRIV; velaglucer-ase alfa	Human gluco-cerebrosidase ERT	Rhu protein, gene-activated	Shire	Protein	Type 1 Gaucher's disease	Mar-ket	Shire PR Feb 10, 2011 - 2010 sales of **US$ 143 mln** (launched in 2010)
								Total: **US$ 2.577 bln** (US$ 2.422 bln in 2009)

Group 13: Follicle Stimulating Hormone (FSH)								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
1319	Puregon / Follistim; follitropin beta	Follicle Stimulating Hormone (FSH) receptor	Rhu glycoprotein produced in CHO cells (in vials and cartridges)	Merck & Co. (acquired Schering-Plough) (ex Organon))	Protein	Development of multiple follices in ovulatory women and in anovulatory infertile women	Mar-ket	Merck & Co 2010 Sales Feb 3, 2011 - 2010 sales of **US$ 528 mln** (-3% vs previous year)
1260	Gonal-f; rec follitropin alpha; GONALEF; FSH	Follicle Stimulating Hormone (FSH)	Rec human protein	Merck Serono	Protein	Induction of ovulation and pregnancy in functionally infertile pts	Mar-ket	Merck KGaA PR Feb 21, 2011 - 2010 sales of € 504 mln (+3.7% vs previous year) = **US$ 674 mln**
								Total: **US$ 1.202 bln** (US$ 1.206 bln in 2009)

Group 14: Antiviral Antibody								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
734	Synagis; palivizumab; MEDI-493;	Epitope on RS virus	Rec humanized full mab	AstraZeneca (MedImmune)	Antibody	Propylaxis of RSV infection	Mar-ket	AstraZenca 2010 Earnings Jan 27, 2011 - 2010 sales of **US$ 1,038 mln** (-4% vs previous year)

Group 15: Other Antibodies

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
217	ReoPro; abciximab	Glycoprotein IIb/IIIa antagonist	Fab fragment of chimeric mab 7E3	Eli Lilly & Centocor (J&J)	Antibody	Adjunct to PCI (percutaneous coronary interventions)	Mar-ket	Lilly Product Sales Jan 27, 2011 - 2010 sales of **US$ 205.2 mln** (-11% vs previous year)
1236	Prolia; denosumab; AMG-162	Receptor Activator for Nuclear Factor kappa B Ligand (RANKL)	Rec fully human IgG2 mab	Amgen & Daiichi-Sankyo & GlaxoSmithKline (GSK)	Antibody	Postmenopausal osteoporosis	Mar-ket	Amgen PR Jan 24, 2011 - First sales in 2010 after approval in the US and internationally were **US$ 33 mln**
145	Nplate; romiplostim; AMG-531	Thrombopoietin (TPO) receptor agonist	Rec peptibody: dimeric TPO-R BDs + Fc of IgG1	Amgen	Antibody	Idiopathic thrombocytopenic purpura resistant to splenectomy	Mar-ket	Amgen PR Jan 24, 2011 - 2010 sales were **US$ 229 mln** (+108% vs previous year)
								Total: US$ 0.467 bln

Group 16: Other Proteins - I

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	R&D Stage	Message
10107	Botox; onabotulinumtoxinA	Neuromuscular transmission (SNAP-25 cleavage)	Neurotoxin from Clostridium botulinum type A	Allergan Pharmaceuticals & GlaxoSmithKline Japan & China)	Protein	Medical and esthetic indications	Market	Allergan Q4 Shareholder Transcript Feb 2, 2011 - 2010 Botox sales grew 8% over 2010 sales (US$ 1,309.6 mln) to **US$ 1,414 mln**
440	Pulmozyme; dornase alfa	DNA	Rhu enzyme delivered with nebulizer	Roche (Genentech)	Protein	Cystic fibrosis	Market	Roche Financial Report 2010 - 2010 sales of CHF 513 mln (+6% vs previous year) = **US$ 554 mln**
10016	InductOs; rhBMP-2/ACS; dibotermin alfa applied to Absorbable Collagen Sponge	Bone regeneration	Rhu bone morphogenic protein on collagen matrix	Pfizer (acquired Wyeth) & Astellas Pharma	Medical device & biomaterial	Acute tibia fractures; lower back spine fusion surgery (plus cage)	Market	Pfizer 2010 Earnings PR Feb 1, 2011 - Pfizer's 2010 sales of BMP-2 in Medtronic products were **US$ 400 mln**
151	TNKase; Metalyse; tenecteplase TNK-t-PA	Plasminogen activator	Rec engineered t-PA (3 aa substituted)	Roche (Genentech) & Boehringer Ingelheim	Protein	Acute myocardial infarction	Market	Roche Financial Report 2010 - Combined 2010 sales of TNKase and Activase were CHF 460 mln (+4% vs previous year)**;** BI results not yet published **= US$ 496 mln**
1564	Dysport (EU); Reloxin (US); abobotulinumtoxinA	Neuromuscular transmission (SNAP-25 cleavage)	Neurotoxin protein for injection	Ipsen	Protein	Cervical dystony	Market	Ipsen PR Feb 2, 2011 - 2010 sales of € 183.7 mln (7.7% vs previous year) ; Ipsen's sales figure includes supply to Medicis and Galderma = **US$ 253 mln**

Group 16: Other Proteins - II								
ID No.	**Product Name**	**Target / Mechanism of Action**	**Class of Compound**	**Company**	**Product Category**	**Indication**	**R&D Stage**	**Message**
10063	Thyrogen; TSH alfa for injection	Thyroid hormone receptor stimulator	Rec human thyrotropin (TSH) for injection	Genzyme	Protein	Adjunctive treatment in thyroidectomy for well-differentiated thyroid cancer	Market	Genzyme 2010 Earnings PR Feb 16, 2011 - 2010 sales of **US$ 182 mln** (+6.7% vs previous year)
64	Xigris; drotrecogin-alpha; rhu activated protein C	F. Va + F. VIIIa; PAI-1; TNF; thrombin	Rec hu protein	Eli Lilly & Teijin	Protein	Severe sepsis	Market	Lilly Product Sales Jan 27, 2011 - 2010 sales of **US$ 104 mln** (-18% vs previous year)
6686	Kineret; anakinra;	Interleukin-1 receptor (IL-1R) antagonist	Rhu protein (non-glycosylated, N-terminal methionin)	Biovitrum (from Amgen)	Protein	Rheumatoid arthritis	Market	Swedish Orphan Biovitrum Annual Report 2010 - 2010 global sales of SEK 422.3 mln = **US$ 67 mln**
1149	Increlex; mecasermin; rhIGF-1	Insulin-like growth factor-1 (IGF-1) receptor agonist	Rhu growth factor	Ipsen (acquired Tercica)	Protein	Severe forms of primary IGF deficiency (IGFD) in children	Market	Ipsen PR Feb 2, 2011 - 2010 sales of € 26.1 mln (+19.5% vs previous year) = **US$ 40 mln**
1785	Kepivance; palifermin; rhu KGF-1; FGF-7	Keratinocyte growth factor receptor	Rec human KGF	Biovitrum (from Amgen)	Protein	Severe oral mucositis in pts with hematologic cancers undergoing bone marrow transplantation	Market	Swedish Orphan Biovitrum Annual Report 2010 - 2010 global sales of SEK 94.8 mln = **US$ 15 mln**
								Total = **US$ 3.525 bln**

La Merie's Competitor Analysis **Reports** provide you with the data you need for your competitive intelligence evaluations: • *Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors* • *Biosimilar and Biobetter/Biosuperior Antibodies* • *Cancer Antibodies in Early Clinical Development* • *Antibody Therapy of Inflammatory and Autoimmune Diseases* • *Anti-Infective Antibodies*	Use our **R&D Database** for your structured searches and preparation of your own reports or presentations: • *Full R&D Drug Pipeline Database: 1-Year Subscription* • *Antibody Pipeline Database: 1-Year Subscription* • *Therapeutic Protein Pipeline Database: 1-Year Subscription* • *Oncology Pipeline Database: 1-Year Subscription*
Flat-Rate Subscription to **La Merie Reports** **with 24/7 Online Access**	La Merie **Full Reports:** • *Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers* • *Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competive Landscape and R&D Pipeline Analysis of Hemostasis Proteins*

Learn more about R&D Pipeline News

R&D Pipeline News is your weekly tool for biopharmaceutical R&D analysis and it's available by annual subscription.

R&D Pipeline News will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given Target, Technology or Company.

The R&D information is presented in an easy- and rapid-to-screen tabular format and grouped either in Therapeutic Areas or Product Categories, saving you time in your research.

Where can I get a subscription?

At our Online Store:
http://www.pipelinereview.com/store/periodicals.html

Or contact us at **sales@lamerie.com**

PipelineReview.com
By La Merie Business Intelligence Center

Why should you use R&D Pipeline News?

- **To keep up-to-date.**

Examine the who, what, when, where of biotechnology R&D.

- **To benchmark your company against the competition**

Keep en eye on your competitors' projects and developments, in which stage they are, their achievements, handicaps, etc…and find out where you are standing in the market.

- **To save time in your research**

Get the crucial information, in a one-shot tabular screen grouped in Therapeutic Areas or Product Categories, and deepen easily in those articles in which you are interested with just one-click.

- **To identify new business enterprises**

Recognize new business opportunities: joint ventures, licensing partners, co-marketing partners, etc..

- **To receive news right in time**

Get your personal copy every monday delivered by e-mail.